Apixaban plasma concentrations in patients with obesity.
Fadiea Al-AieshyMika SkeppholmJonas FyrestamFredrik JohanssonAnton PohankaRickard E MalmströmPublished in: European journal of clinical pharmacology (2024)
Apixaban exposure did not vary substantially between obese and normal weight matched controls, implying that general dose adjustments are not required. However, vast interindividual variability was observed in patients with obesity, suggesting that measuring the concentrations could be valuable for specific patients. Further research is needed to identify which specific patients may benefit from this approach.
Keyphrases
- weight loss
- end stage renal disease
- metabolic syndrome
- ejection fraction
- type diabetes
- newly diagnosed
- chronic kidney disease
- insulin resistance
- venous thromboembolism
- prognostic factors
- atrial fibrillation
- adipose tissue
- weight gain
- physical activity
- patient reported outcomes
- bariatric surgery
- skeletal muscle
- high fat diet induced
- patient reported
- obese patients